

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the “**Effective Date**”) by and between

Yariv MAZOR, an Israeli citizen of AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America (“**Assignors**”); and

ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership under no. 2810992, with registered office address at 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America (“**Assignee**”)

WHEREAS


- A. Assignors have made certain inventions (the “**Inventions**”) in respect of which the patent applications identified in the attached Schedule have been filed (the “**Applications**”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Yariv MAZOR

Date 11/23/2022

Signed for and on behalf of
ASTRAZENECA PHARMACEUTICALS LP
Name:
Title: Authorised Signatory

Date _____

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the “**Effective Date**”) by and between

Yariv MAZOR, an Israeli citizen of AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America (“**Assignors**”); and

ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership under no. 2810992, with registered office address at 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America (“**Assignee**”)

WHEREAS

- A. Assignors have made certain inventions (the “**Inventions**”) in respect of which the patent applications identified in the attached Schedule have been filed (the “**Applications**”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Yariv MAZOR

Date _____



Signed for and on behalf of
ASTRAZENECA PHARMACEUTICALS LP

Name: *Patrick Scott Alban*

Title: Authorised Signatory

Date *February 15, 2023*

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the “**Effective Date**”) by and between

Frank Irvine COMER, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Srinath KASTURIRANGAN, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Qun DU, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Chunning YANG, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America (“**Assignors**”); and

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America (“**Assignee**”)

WHEREAS

- A. Assignors have made certain inventions (the “**Inventions**”) in respect of which the patent applications identified in the attached Schedule have been filed (the “**Applications**”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any

proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Frank Irvine COMER

Date 2 December 2022

Srinath KASTURIRANGAN

Date _____

Qun DU

Date _____

Chunning YANG

Date _____

Signed for and on behalf of
MEDIMMUNE, LLC

Name:

Title: Authorised Signatory

Date _____

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the "**Effective Date**") by and between

Frank Irvine COMER, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;

Srinath KASTURIRANGAN, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;

Qun DU, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;

Chunning YANG, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America ("**Assignors**"); and

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America ("**Assignee**")

WHEREAS

- A. Assignors have made certain inventions (the "**Inventions**") in respect of which the patent applications identified in the attached Schedule have been filed (the "**Applications**").
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "**Rights**"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any

proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.


4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Frank Irvine COMER

Date _____



Srinath KASTURIRANGAN

Date 02/02/2023

Qun DU

Date _____

Chunning YANG

Date _____

Signed for and on behalf of
MEDIMMUNE, LLC

Name:

Title: Authorised Signatory

Date _____

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the “**Effective Date**”) by and between

Frank Irvine COMER, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Srinath KASTURIRANGAN, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Qun DU, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Chunning YANG, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America (“**Assignors**”); and

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America (“**Assignee**”)

WHEREAS

- A. Assignors have made certain inventions (the “**Inventions**”) in respect of which the patent applications identified in the attached Schedule have been filed (the “**Applications**”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any

proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Frank Irvine COMER

Date _____

Srinath KASTURIRANGAN

Date _____

Qun DU

Date 12/6/22

Chunning YANG

Date _____

Signed for and on behalf of
MEDIMMUNE, LLC

Name:

Title: Authorised Signatory

Date _____

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the “Effective Date”) by and between

Frank Irvine COMER, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Srinath KASTURIRANGAN, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Qun DU, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Chunning YANG, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America (“Assignors”); and

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America (“Assignee”)

WHEREAS

- A. Assignors have made certain inventions (the “Inventions”) in respect of which the patent applications identified in the attached Schedule have been filed (the “Applications”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “Rights”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any

proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Frank Irvine COMER

Date _____

Srinath KASTURIRANGAN

Date _____

Qun DU

Date _____


Chunning YANG

Date 11/29/2022

Signed for and on behalf of
MEDIMMUNE, LLC

Name:

Title: Authorised Signatory

Date _____

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the “**Effective Date**”) by and between

Frank Irvine COMER, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Srinath KASTURIRANGAN, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Qun DU, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America;
Chunning YANG, a US citizen of MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States of America (“**Assignors**”); and

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America (“**Assignee**”)

WHEREAS

- A. Assignors have made certain inventions (the “**Inventions**”) in respect of which the patent applications identified in the attached Schedule have been filed (the “**Applications**”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any

proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Frank Irvine COMER

Date _____

Srinath KASTURIRANGAN


Date _____

Qun DU

Date _____

Chunning YANG

Date _____


Signed for and on behalf of
MEDIMMUNE, LLC

Name: Patrick Scott Alban
Title: Authorised Signatory

Date February 15, 2023

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the "Effective Date") by and between

Andrew Grier BUCHANAN, a British citizen of MedImmune Limited, Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom ("Assignors"); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales whose registered office is Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom ("Assignee")

WHEREAS


- A. Assignors have made certain inventions (the "Inventions") in respect of which the patent applications identified in the attached Schedule have been filed (the "Applications").
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Andrew Grier BUCHANAN

Date 7 Dec 2022



Signed for and on behalf of
MEDIMMUNE LIMITED

Name: Alison McF MEE

Title: Authorised Signatory

Date 13 February 2023

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the “Effective Date”) by and between

ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership under no. 2810992, with registered office address at 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America (“Assignor”); and

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under no. 3674842, with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“Assignee”).

WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s entire right, title and interest in and to the patent applications identified in the attached Schedule (the “Applications”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “Rights”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.


5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Signed for and on behalf of
ASTRAZENECA PHARMACEUTICALS LP
Name: *Patrick Scott Alban*
Title: Authorised Signatory

Date *February 15, 2023*



Signed for and on behalf of
ASTRAZENECA UK LIMITED
Name: *Andrew Cook*
Title: Authorised Signatory

Date *21 February 2023*

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the “**Effective Date**”) by and between

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under no. 3674842, with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“**Assignor**”); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales under no. 2451177, with registered office address at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (“**Assignee**”).


WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s entire right, title and interest in and to the patent applications identified in the attached Schedule (the “**Applications**”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.


5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Signed for and on behalf of
ASTRAZENECA UK LIMITED
Name: Andrew COOK
Title: Authorised Signatory

Date 21 February 2023



Signed for and on behalf of
MEDIMMUNE LIMITED
Name: Mark NESS
Title: Authorised Signatory

Date 22 February 2023

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9 November 2022 (the "**Effective Date**") by and between

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America ("**Assignor**"); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales under no. 2451177, whose registered office is Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom ("**Assignee**").


WHEREAS, Assignor has agreed to assign to Assignee the Assignor's entire right, title and interest in and to the patent applications identified in the attached Schedule (the "**Applications**") and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "**Rights**"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


Signed for and on behalf of
MEDIMMUNE, LLC
Name: *Patrick Scott Alban*
Title: Authorised Signatory

Date *February 15, 2023*


Signed for and on behalf of
MEDIMMUNE LIMITED
Name: *Mark NESS*
Title: Authorised Signatory

Date *22 February 2023*

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 22 February 2023 (the “Effective Date”) by and between

MEDIMMUNE LIMITED, a company incorporated in England and Wales under no. 2451177, with registered office address at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (“Assignor”); and

ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482, with registered office address at SE-151 85 Södertälje, Sweden (“Assignee”).

WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s entire right, title and interest in and to the patent applications identified in the attached Schedule (the “Applications”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “Rights”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Signed for and on behalf of
MEDIMMUNE LIMITED
Name: Mark NESS
Title: Authorised Signatory

Date 22 February 2023



Signed for and on behalf of
ASTRAZENECA AB
Name: Alison MCGHEE
Title: Authorised Signatory

Date 22 February 2023

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-AR-NP	Argentina	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-WO-PCT	International	PCT	PCT/EP2022/081225	9 November 2022
EGFCM-100-PK-NP	Pakistan	National	ANTIBODY MOLECULES AND CONJUGATES	10 November 2022
EGFCM-100-TW-NP	Taiwan	National	111143063	10 November 2022
EGFCM-100-US-NP	USA	National	18/053,955	9 November 2022

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
EGFCM-100-US-PSP	USA	Provisional	63/263,835	10 November 2021

PCT

(Original in Electronic Form)

VIII-2-1	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name	In relation to this international application MEDIMMUNE LIMITED is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-1 (iv)		an assignment from COMER, Frank Irvine to MEDIMMUNE, LLC, dated 25 April 2022 (25.04.2022)
VIII-2-1 (iv)		an assignment from KASTURIRANGAN, Srinath to MEDIMMUNE, LLC, dated 09 May 2022 (09.05.2022)
VIII-2-1 (iv)		an assignment from DU, Qun to MEDIMMUNE, LLC, dated 05 May 2022 (05.05.2022)
VIII-2-1 (iv)		an assignment from YANG, Chunning to MEDIMMUNE, LLC, dated 19 April 2022 (19.04.2022)
VIII-2-1 (iv)		an assignment from MEDIMMUNE, LLC to MEDIMMUNE LIMITED, dated 10 May 2022 (10.05.2022)
VIII-2-1 (iv)		an assignment from BUCHANAN, Andrew Grier to MEDIMMUNE LIMITED, dated 28 May 2022 (28.05.2022)
VIII-2-1 (iv)		an assignment from MAZOR, Yariv to ASTRAZENECA PHARMACEUTICALS LP, dated 19 April 2022 (19.04.2022)
VIII-2-1 (iv)		an assignment from ASTRAZENECA PHARMACEUTICALS LP to ASTRAZENECA UK LIMITED, dated 20 April 2022 (20.04.2022)
VIII-2-1 (iv)		an assignment from ASTRAZENECA UK LIMITED to MEDIMMUNE LIMITED, dated 07 June 2022 (07.06.2022)